Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 9/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 9/20 | 0.43 |
| ▸ | IGFBP3 | P17936 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21657031 | 0.90 | PARP10 (0.46) | LPAR1LPAR5IGFBP3 | |
| SCHEMBL21656908 | 0.89 | ALDH1A1 (0.46) | LMNAMAPK1LPAR1LPAR5 | |
| SCHEMBL21656937 | 0.89 | SLC6A2 (0.45) | LPAR1LPAR5IGFBP3 | |
| SCHEMBL21657024 | 0.89 | ALDH1A1 (0.36) | MAPK1LPAR1LPAR5 | |
| SCHEMBL23228801 | 0.88 | RAB9A (0.45) | RAB9ALMNAMAPK1HTTNPC1 | |
| SCHEMBL21628475 | 0.83 | RAB9A (0.63) | RAB9ALMNAMAPK1HTTNPC1 | |
| SCHEMBL20470550 | 0.82 | RAB9A (0.42) | RAB9ALMNAMAPK1NPC1POLB | |
| SCHEMBL19357374 | 0.80 | RAB9A (0.56) | RAB9ALMNAMAPK1HTTNPC1 | |
| SCHEMBL23228767 | 0.78 | PARP10 (0.44) | MAPK1IGFBP3 | |
| SCHEMBL23228792 | 0.77 | ALDH1A1 (0.44) | LMNAMAPK1IGFBP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591289-B2 | Aromatic compounds | AHR, TYR, MUSK | RAB9A 3345/4885LMNA 3083/4885MAPK1 3401/4885 |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | RAB9A 2955/4885LMNA 3327/4885MAPK1 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.